# Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

> **NCT00492544** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Cervarix™ (HPV-16/18 L1 VLP AS04)

## Key facts

- **NCT ID:** NCT00492544
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-02
- **Primary completion:** 2008-03-28
- **Final completion:** 2008-03-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492544, "Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00492544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*